ArticleBMJ (Clinical research ed.)2024
Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.
No numbers read from the abstract.